



(51) International Patent Classification:

C07D 498/04 (2006.01) A61P 25/00 (2006.01)
A61K 31/55 (2006.01)

(21) International Application Number:

PCT/US2014/010577

(22) International Filing Date:

8 January 2014 (08.01.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/752,203 14 January 2013 (14.01.2013) US

(71) Applicant: ELI LILLY AND COMPANY [US/US];
Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventor: GALLAGHER, Peter, Thaddeus; c/o Eli Lilly
and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US).

(74) Agents: TUCKER, R. Craig et al.; Eli Lilly and Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS



(57) Abstract: A dual H1 inverse agonist/5-HT2A receptor antagonist of the formula: [Formula I], its uses, and methods for its preparation are described.

**(THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS
AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT_{2A} ANTAGONISTS**

Histamine plays an important role in a variety of physiological processes through
5 its interaction with at least four different G-protein coupled receptors, the H1-H4
receptors. In the CNS, H1 receptors play a key role in the sleep regulation cycle and H1
antagonists/inverse agonists are known to induce somnolence.

Likewise, serotonin plays important roles in a variety of physiological processes
through its interaction with at least fourteen different G-protein coupled receptors.
10 Modulation of 5-HT_{2A} receptors in the CNS plays a key role in the sleep regulation cycle
and 5-HT_{2A} antagonists have been shown to improve slow wave sleep and sleep
maintenance in patients with insomnia.

Compounds having H1 or 5-HT_{2A} inverse agonist or antagonist activity have been
used in the treatment of insomnia (e.g. doxepin and trazodone, respectively) and have
15 exhibited significant pharmacological effects in animal sleep studies. However, no
selective dual activity H1/5-HT_{2A} inverse agonists/antagonists are currently commercially
available.


WO 2007/022068 describes certain substituted (thieno[2,3-b][1,5]benzodiazepine-
4-yl)piperazin-1-yl and (thieno[2,3-b][1,5]benzoxazepine-4-yl)piperazin-1-yl compounds
20 for treating sleep disorders.

The present invention provides 3-[4-(2-cyclopropyl-8-methyl-thieno[2,3-
b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-propanoic acid and pharmaceutically
acceptable salts thereof, having high inverse agonist potency for the H1 receptor, high
antagonist potency for the 5-HT_{2A} receptor, and good selectivity for these receptors,
25 particularly as against other histamine receptors, serotonin receptors and other
physiologically relevant receptors, particularly as against the 5-HT_{2C} receptor, GABA_A
receptor, muscarinic receptors, dopaminergic receptors, adrenergic receptors, and the
hERG channel. These compounds also demonstrate through animal models that they may
be useful for the treatment of sleep disorders characterized by poor sleep maintenance.
30 As such, the compounds are believed to be useful for the treatment of sleep disorders
characterized by poor sleep latency or poor sleep maintenance or both, such as the
treatment of insomnia, as for example chronic or transient primary insomnia, or chronic

-2-

or transient secondary insomnia, or both. Examples of secondary insomnia include, but are not limited to insomnia associated with depressive disorders (e.g. major depressive disorder, dysthymia, and/or cyclothymia), insomnia associated with anxiety disorders (e.g. generalized anxiety disorder and/or social phobia), insomnia associated with pain
 5 (e.g. fibromyalgia, chronic bone or joint pain, such as associated with inflammatory arthritis or osteoarthritis, or diabetic neuropathic pain), insomnia associated with allergic reactions (e.g. allergic asthma, pruritus, rhinitis, congestion, etc.), insomnia associated lung or airway disorders (e.g. with obstructive sleep apnea, reactive airway disease, etc.), insomnia associated with psychiatric disorders, dementia, and/or neurodegenerative
 10 diseases, and/or insomnia associated with circadian rhythm sleep disorders (e.g. shift work sleep disorder, jet lag disorder, delayed sleep phase disorder, advanced phase sleep disorder, and non-24 hr. sleep-wake syndrome, etc.).

The present invention provides a compound of Formula I



15

I

or a pharmaceutically acceptable salt thereof. That is to say 3-[4-(2-cyclopropyl-8-methylthieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-propanoic acid or a pharmaceutically acceptable salt thereof.

20

In another aspect of the invention there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier, diluent, or excipient. Furthermore, this aspect of the invention provides a pharmaceutical composition for treating insomnia, as for example insomnia characterized by prolonged sleep latency or
 25 poor sleep maintenance or both, as for example primary insomnia, jet lag, shift work sleep disorder, delayed sleep phase disorder, advanced phase sleep disorder, and/or non-

24 hr. sleep-wake disorders, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents.

5 A further embodiment of this aspect of the invention provides a pharmaceutical composition comprising a compound according to Formula I, or pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier, excipient or diluent, and optionally other therapeutic ingredients.


10 The present invention also provides a method of treating insomnia, as for example insomnia characterized by prolonged sleep latency or poor sleep maintenance or both, as for example primary insomnia, jet lag, shift work sleep disorder, delayed sleep phase disorder, advanced phase sleep disorder, and/or non-24 hr. sleep-wake disorders, in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. In one particular embodiment of these methods of treatment, the mammal is a human.

15 This invention also provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in therapy. Within this aspect, the invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment of insomnia. In further embodiments, the insomnia is characterized by prolonged sleep latency or poor sleep maintenance or both, as for example primary insomnia, jet lag, shift work sleep disorder, delayed sleep phase disorder, advanced phase sleep disorder, and/or non-24 hr. sleep-wake disorders. One particular embodiment of this aspect of the inventions, the uses are in mammals, particular humans.

25 Another aspect of this invention provides the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of insomnia, as for example primary insomnia characterized by prolonged sleep latency or poor sleep maintenance or both, as for example primary insomnia, jet lag, shift work sleep disorder, delayed sleep phase disorder, advanced phase sleep disorder, and/or non-24 hr. sleep-wake disorders.

30 For clarity, the following numbering of the tricyclic ring structure will be used throughout the application:

-4-



The compound of this invention has basic and acidic moieties, and accordingly reacts with a number of organic and inorganic acids and bases to form pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the compound of the present invention are contemplated within the scope of the present application. The term "pharmaceutically acceptable salt" as used herein, refers to any salt of a compound of the invention that is substantially non-toxic to living organisms. Such salts include those listed in Journal of Pharmaceutical Science, **66**, 2-19 (1977), which are known to the skilled artisan.

10

Abbreviations used herein are defined as follows:

"Brine" means saturated aqueous NaCl solution.

"DMEM" means Dulbecco's Minimum Eagle's Medium.

"DMSO" means dimethyl sulfoxide.

15

"EDTA" means ethylenediaminetetraacetic acid.

"Equiv" means equivalent(s).

"FBS" means fetal bovine serum.

"HEPES" means 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid.

"HPLC" means high pressure liquid chromatography.

20

"hr." means hour or hours.

"IC₅₀" means the concentration at which 50% of the maximum inhibition is achieved.

"LC-MS" means HPLC-mass spectrography.

"MeOH" means methanol.

-5-

“min.” means minute or minutes.

“MS” means mass spectroscopy.

“MS (ES+)” means mass spectroscopy using electrospray ionization.

“NMR” means nuclear magnetic resonance.


5 “RO” means receptor occupancy.

“THF” means tetrahydrofuran.

General Chemistry


The compound of the present invention can be prepared according to the
10 following synthetic examples.

Preparation 1. 2,5-dichlorothiophene-3-carbonyl chloride



To a suspension of 2,5-dichloro-thiophene-3-carboxylic acid (49.7 g; 252.23
mmoles; 1.00 equiv) in dichloromethane (500 mL), add dimethylformamide (0.5 mL;
15 6.47 mmoles) followed by a solution of 2 M oxalyl chloride in dichloromethane (138.73
mL; 277.45 mmoles; 1.1 equiv) over 1.5 hr. (vent the evolved gas through a caustic
solution). Stir the resulting clear solution at room temperature for 1 hr. until gas
evolution has ceased and the reaction is complete by LCMS (quench a sample into 7 M
20 NH_3/MeOH for reaction monitoring) MS (m/z): = 195.9, 197.9 (M+H)⁺ for
corresponding primary amide. Evaporate to dryness to give the title intermediate as a
brown oil (55 g, 252 mmol, quantitative).

Preparation 2. 2,5-dichloro-N-(2-hydroxy-4-methyl-phenyl)thiophene-3-carboxamide




25

-6-

To a solution of 6-amino-*m*-cresol (34.14 g; 277.20 mmols; 1.1 equiv) in THF (450 mL), add pyridine (40.76 mL; 504.00 mmols; 2 equiv), followed by a solution of 2,5-dichlorothiophene-3-carbonyl chloride (54.30 g, 252 mmols, 1.00 equiv) in THF (250 mL) over 30 min., using an ice-bath to maintain a temperature of 15-20°C. Stir the
 5 resulting thick mixture at room temperature for 1 hr. to give complete consumption of the aminophenol by LCMS. Pour onto a mixture of 2 M aqueous HCl (500 ml) and ice (250 ml) with agitation. Collect the resulting beige solid by filtration, wash well with water, and dry in air. MS (m/z): = 301.84, 303.94 (M+H)⁺. Dry in a vacuum oven at 40°C over P₂O₅ overnight to give the title intermediate (84.5g, assume quantitative).


10

Preparation 3. 2-chloro-8-methyl-5H-thieno[2,3-b][1,5]benzoxazepin-4-one



To a well-stirred suspension of 2,5-dichloro-N-(2-hydroxy-4-methylphenyl)thiophene-3-carboxamide (76.15 g; 252 mmols; 1.00 equiv) in dimethyl
 15 sulfoxide (450 mL), add potassium carbonate (38.31 g; 277.20 mmols; 1.1 equiv) and heat the mixture to 100-110°C for 4.5 hr. to give essentially complete conversion by LCMS. Allow to cool to room temperature and slowly add to two separate beakers containing 1 M aqueous hydrochloric acid (500 ml), observing gas evolution. Stir at
 20 room temperature for 0.5 hr. and collect the resulting dark grey solid by filtration. Wash sequentially with water, followed by a small amount of ethanol, followed by a small amount of diethyl ether. Dry in a vacuum oven at 45°C overnight to give the title intermediate (58.5g, 87%). MS (m/z): = 265.99 (M+H)⁺.

Preparation 4. 2,4-dichloro-8-methyl-thieno[2,3-b][1,5]benzoxazepine




25

-7-

Charge a 1 L round bottom flask with methoxybenzene (225 mL, 5V), 2-chloro-8-methyl-5H-thieno[2,3-b][1,5]benzoxazepin-4-one (45 g; 169.4 mmols; 1 equiv) and N,N-dimethylaniline (47.2 g; 389.5 mmols; 2.3 equiv). Heat to 60°C and add phosphoryl chloride (85.7 g; 558.9 mmols; 3.3 equiv) drop wise over 0.5 hr. Warm up to 100°C and stir for 2 hr. until complete by TLC analysis. Cool to 40-60°C and evaporate to obtain the title intermediate as a dark brown solid (123.1 g, 433.2 mmols, 256% yield uncorrected by assay). MS (m/z): 283.8 (M+H).


Preparation 5. Methyl 3-[4-(2-chloro-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-propanoate



Charge a 1 L round bottom flask with 2,4-dichloro-8-methyl-thieno[2,3-b][1,5]benzoxazepine (121.1 g; 169.4 mmols; 1.0 equiv), followed by acetonitrile (600 mL, 12.5V), then potassium carbonate (119.4 g; 863.9 mmols) in one portion. Stir for 10-20 min. and then add methyl 2,2-dimethyl-3-(piperazin-1-yl)propanoate dihydrochloride (55.54 g; 203.3 mmols; 1.2 equiv) in one portion. Heat to 80°C and stir for 30 hr. Concentrate the mixture to dryness under vacuum, then charge ethyl acetate (1920 mL, 40V) and water (1920 mL, 40V) into the mixture. Stir, filter and then separate the water phase and extract with ethyl acetate (960 mL, 20V). Combine the organic phases and wash with water (960 mL × 2) and brine (200 mL, 4V). Concentrate and purify by silica gel column (petroleum ether/ethyl acetate (0 to 10%)) to obtain the title intermediate as a yellow solid (55.4 g, 123.7 mmols, 95.8% purity, 73.0% yield uncorrected by assay). MS (m/z): 448.2 (M+H). ¹H NMR (400MHz,CDCl₃):δ7.03 (d, *J* = 8.8 Hz, 1H), 6.91 (d, *J* = 1.6 Hz, 1H), 6.81 (s, 1H), 6.50 (s, 1H), 3.67(s, 3H), 3.47 (t, *J* = 4.4 Hz, 4H), 2.58-2.54 (q, 6H), 2.28 (s, 3H), 1.19 (s, 6H).

-8-


Preparation 6. Methyl 3-[4-(2-cyclopropyl-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-propanoate



Degas a mixture of methyl 3-[4-(2-chloro-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-propanoate (30.00 g, 66.97 mmol), cyclopropylboronic acid (7.48 g, 87.06 mmol), tribasic potassium phosphate n-hydrate (49.75 g, 234.38 mmol), tricyclohexylphosphine tetrafluoroborate (2.47 g, 6.7 mmol), water (13.39 mL, 13.39 g, 743.4 mmol) and toluene (267.87 mL, 233.36 g, 2.53 mol) with nitrogen for 10 min. Add palladium (II) acetate (0.751 g, 3.35 mmol) and stir at 100°C overnight. Allow the reaction mixture to cool to room temperature, add water and extract the reaction mixture with ethyl acetate. Dry the ethyl acetate extract (Na₂SO₄), concentrate and chromatograph on silica (ISCO) and gradient elute with ethyl acetate / isohexane (0%:100% to 20%:80%). Collect fractions containing product and concentrate. Chromatograph further using supercritical fluid (CO₂) chromatography with 25 % ethanol and 0.2% dimethylamine. Collect fractions containing product, concentrate and dry the resultant solid in vacuo for 6 hr. at 40°C to give methyl 3-[4-(2-cyclopropyl-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-propanoate (23.73 g, 82.93%) MS (m/z): 454.25 (M+H). ¹H NMR (300.11 MHz, CDCl₃): 6.98 (d, J= 7.9 Hz, 1H), 6.88 (dd, J= 1.4, 8.0 Hz, 1H), 6.81 (d, J= 1.5 Hz, 1H), 6.29 (d, J= 0.9 Hz, 1H), 3.67 (s, 3H), 3.50-3.47 (m, 4H), 2.58-2.54 (m, 6H), 2.27 (s, 3H), 1.94-1.89 (m, 1H), 1.58 (s, 1H), 1.19 (s, 6H), 0.94-0.87 (m, 1H), 0.65-0.59 (m, 1H).


Example 1. 3-[4-(2-Cyclopropyl-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-propanoic acid

-9-



Add sodium hydroxide (9.27 g, 231.68 mmol) to a slurry of methyl 3-[4-(2-cyclopropyl-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethylpropanoate (35.03 g, 77.23 mmol) in water (210.18 mL) and isopropyl alcohol (210.18 mL) and heat to 85 °C for 45 min. Cool to room temperature and neutralize with 2M hydrochloric acid to pH 6-6.5. Concentrate the mixture to remove the isopropyl alcohol and isolate the resultant precipitate by filtration and wash on the sinter. Dry the isolated solid in vacuo at 40°C overnight to give 3-[4-(2-cyclopropyl-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid (32.6 g, 95.12% yield). MS (m/z): 440.1 (M+H). ¹H NMR (300.11 MHz, CDCl₃): 7.03 (d, J = 7.9 Hz, 1H), 6.92 (dd, J = 1.3, 8.1 Hz, 1H), 6.84 (d, J = 1.3 Hz, 1H), 6.32 (d, J = 0.9 Hz, H), 3.70 (s, 4H), 2.88 (t, J = 4.6 Hz, 4H), 2.62 (s, 2H), 2.30 (s, 3H), 1.97-1.91 (m, 1H), 1.28 (s, 6H), 0.98-0.91 (m, 2H), 0.67-0.62 (m, 2H).

15 Example 2. 3-[4-(2-Cyclopropyl-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid dihydrochloride



Add 2 M hydrochloric acid (0.119 mL, 0.24 mmol) to a suspension of 3-[4-(2-cyclopropyl-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-

propanoic acid (0.0497 g, 0.11 mmol) in acetonitrile (1 mL) and water (1 mL) and lyophilize to give of 3-[4-(2-cyclopropyl-8-methyl-thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl]-2,2-dimethyl-propanoic acid dihydrochloride (0.058 g, 100%). MS (m/z): 440.2 (M+H).

5

Literature data (Morairty SR, Hedley L, Flores J, Martin R, Kilduff TS. (2008) *Selective 5-HT_{2A} and 5-HT₆ receptor antagonists promote sleep in rats. Sleep* **31**, 34-44.; and Barbier, A.J., and Bradbury, M.J., *Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders*, CNS & Neurological Disorders – Drug Targets, vol 6, pg. 31-43 (2007)) and data generated in non-clinical animal studies support a role for dual activity H1 inverse agonists / 5-HT_{2A} antagonists in the treatment of insomnia and in the symptomatic treatment of insomnia associated with other disorders such as depressive disorders, anxiety disorders, pain, allergies, lung or airway disorders, psychiatric disorders, dementia, and/or neurodegenerative diseases, and/or circadian rhythm sleep disorders. Specifically it is found that certain dual activity H1 inverse agonists / 5-HT_{2A} antagonists are effective in increasing total sleep time using EEG monitored rodents without disproportionate or clinically relevant hypoactivity, decrease in REM sleep, or hypersomnolence.

To further demonstrate the characteristics of the present compounds, they may be run in the following *in vitro* and *in vivo* assays:

In vitro binding and activity assays:

H1 competition binding assay

[³H]-Pyrilamine binding experiments are carried out in SPA (scintillation proximity assay) 96-well format. Membranes used in this assay are prepared from HEK-293 cells stably expressing recombinant H1 receptor (human). The incubation is initiated by the addition of a mixture of WGA PVT SPA beads (1mg/well, Perkin Elmer (MA, USA) RPNQ0001) and 3 μg membranes to assay buffer (67 mM Tris; pH 7.6) containing 3.5 nM [³H]-Pyrilamine and varying concentrations of the test compound (10 point concentration response curves). Non-specific binding is determined in the presence of 10

μM Triprolidine. Samples are incubated for 4 hr. at room temperature (22°C) and then read in a Microbeta® Trilux.

5-HT_{2A} competition binding assay

5 [³H]-Ketanserin binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressing recombinant 5-HT_{2A} receptor (human). The incubation is initiated by the addition of a mixture of WGA YSi SPA beads (1mg/well, Perkin Elmer (MA, USA), RPNQ0011) and 2 μg membranes to assay buffer (67 mM Tris, 0.5 mM EDTA; pH 7.6) containing 3.1 nM
10 [³H]-Ketanserin and varying concentrations of the test compound (10 point concentration response curves). Non-specific binding is determined in the presence of 20 μM 1-(1-naphthyl) piperazine. Samples are incubated for 4 hr. at room temperature (22°C) and then read in a Microbeta® Trilux.

15 5-HT_{2C} competition binding assay

 [¹²⁵I]-(\pm)DOI binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressing recombinant 5-HT_{2C} receptor (human). The incubation is initiated by the addition of a mixture of WGA PVT SPA beads (0.5 mg/well, Perkin Elmer (MA, USA), RPNQ0001)
20 and 2.5 μg membranes to assay buffer (50 mM Tris-HCl, 10 mM MgCl₂, 0.5 mM EDTA, 10 μM pargyline, 0.1% ascorbic acid, pH7.4) containing 0.2 nM [[¹²⁵I]-(\pm)DOI and varying concentrations of the test compound (10 point concentration response curves). Non-specific binding is determined in the presence of 20 μM 1-(1-naphthyl) piperazine. Samples are incubated for 4 hr. at room temperature (22°C) and then read in a
25 Microbeta® Trilux.

Binding data analysis

 Curves are evaluated using a 4-parameter logistic nonlinear equation to obtain the concentration of competitor causing 50% inhibition of radioligand binding (IC₅₀).
30 Equilibrium dissociation constants (K_i) are calculated according to the equation $K_i = \text{IC}_{50}/(1+L/K_d)$, where L equals the concentration of radioligand used in the experiment and K_d equals the equilibrium dissociation constant of the radioligand for the receptor,

-12-

determined from standard saturation analysis or homologous competition experiments.

Reported values for K_i , where n values are indicated, are shown as geometric mean \pm the standard error of the mean (SEM), with the number of replicate determinations indicated by n. Geometric means are calculated by the equation $\text{GeoMean} = 10^{(\text{Average}(\log K_i 1 + \log K_i 2 + \dots + \log K_i n)/\text{sqrt } n)}$.

GABA_A antagonism using native receptors in primary neuronal cultures

Activity of compounds on native GABA_A receptors is evaluated by monitoring calcium fluxes using a 96 well format FLIPR® system (Fluorometric Imaging Plate Reader (FLIPR®, Molecular Devices). Briefly, cortical embryonic neurons are dissociated from E18 rat embryos and plated at optimum density into black-walled, transparent bottom poly-D-lysine coated 96-well FLIPR® plates. After loading the cells with a calcium sensitive dye (Fluo4-AM, Molecular Devices), the cells are bathed in a solution containing low chloride (chloride replaced by gluconate). Under these conditions activation of GABA_A receptors causes an efflux of chloride ions (in the direction of the chemical gradient), which results in membrane depolarization and consequently activation of voltage gated calcium channels (VGCCs). Calcium influx through VGCCs is recorded and analysed offline using the FLIPR® system. For a pharmacological validation of the assay, concentration response curves (CRC) are recorded for the standard agonist (GABA) and standard antagonist (Gabazine). Any effects are determined in CRC mode against a fixed concentration of agonist GABA at 10 μM (equivalent to an EC₉₀ GABA response).

Methods:

The antagonist effects of compounds are quantified using 10-point dose response curves by comparing the peak fluorescent responses to the agonist GABA in the presence and absence of compound. The assay window is defined as the maximal response obtained by GABA at its predetermined EC₉₀ concentration minus the response obtained by a fully inhibiting concentration of gabazine (50 μM). Antagonist effects are calculated as a percent of the assay window. All data are calculated as relative IC₅₀ values using a four-parameter logistic curve fitting program (Prism Graphpad® 3.01). Antagonist potencies for all compounds are compared to gabazine with three replicates in each assay run.

Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologically important receptors such as, but not limited to, the hERG channel, other serotonin receptors (specifically 5-HT_{1B} and 5-HT_{1D} receptors, lack of agonist activity at 5-HT_{2B} receptors, 5-HT_{2C}, 5-HT₅, 5-HT₆, and 5-HT₇ receptors), dopaminergic receptors (specifically D1, D2, and D3), GABA_A receptors, adrenergic receptors and monoamine transporters.

The compound of example 2 is tested essentially as described above and is found to have activity profiles as shown in Table 1.

10 Table 1. Selectivity data

	Example 2
H1 K _i (nM)	43.2
5-HT _{2A} K _i (nM)	10.2
5-HT _{2B} K _i (nM)	118
5-HT _{2B} Agonist EC ₅₀ (nM)	>10000
5-HT _{2B} Antagonist K _b (nM)	93.4
5-HT _{2C} K _i (nM)	493
GABA _A IC ₅₀ (μM)	>100
hERG Channel (μM)	53% inhibition at 10 μM
Dopamine D ₁ K _i (nM)	996
Dopamine D ₂ K _i (nM)	2320
Dopamine D ₃ K _i (nM)	>6280
5-HT _{1D} K _i (nM)	>3980
5-HT ₅ K _i (nM)	3480
5-HT ₆ K _i (nM)	>5830
5-HT ₇ K _i (nM)	>2060
Adrenergic alpha _{1A} K _i (nM)	4620
Adrenergic alpha _{1B} K _i (nM)	>15500
Adrenergic alpha _{2A} K _i (nM)	5920
Adrenergic alpha _{2B} K _i (nM)	1060

Adrenergic α_{2C} K_i (nM)	1380
Serotonin Transporter K_i (nM)	>478
Norepinephrine Transport K_i (nM)	>671
Dopamine Transporter K_i (nM)	>867

Therefore, physiologically relevant doses of the compounds of the invention are expected to provide substantial inhibition of H1 and 5-HT_{2A} receptors *in vivo*, while not substantially interacting with other physiologically relevant receptors, and thus are

5 expected to provide the desired pharmacology while avoiding undesired effects associated with off-target activity. Such undesired effects include, but are not limited to the following: 5-HT_{2C} antagonist activity associated with treatment emergent weight gain, 5-HT_{2B} agonist activity associated with valvulopathy, hERG channel modulation associated with QT prolongation, and GABA_A antagonist activity associated with seizure

10 activity. Furthermore, interference with sleep/wake physiology is avoided by the selectivity over dopamine receptors, other serotonin receptors, adrenergic receptors, and monoamine transporters.

5-HT_{2A} Receptor Occupancy: Receptor occupancy (RO) is assayed to demonstrate

15 antagonist/inverse agonist activity at the 5-HT_{2A} Receptor *in vivo*. Briefly, male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN) weighing approximately 230-280 grams are given ad lib access to food and water until the beginning of the 3-hr. experimental protocol. 1 mg/kg ketanserin (non-selective 5-HT_{2A} antagonist) is used as a positive control to establish assay validity. Test compounds or control are administered

20 by oral gavage in a vehicle comprised of 20% hydroxypropyl beta-cyclodextrin. MDL 100907 ((R)-(+)- α -(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol), a selective 5-HT_{2A} antagonist, is used as a tracer. MDL 100907 is suspended in water with 5 μ l dilute lactic acid (1 mg/ml), diluted to 6 μ g/ml with saline, and administered in a volume of 1 mL/kg intravenously via the lateral tail vein to yield a

25 tracer dose of 3 μ g/kg. Rats are administered test compound, ketanserin, or vehicle (N = 4), followed 1 hr. later with an intravenous, 3 μ g/kg tracer dose of MDL 100907. It is at

the time of tracer administration that RO is considered to be measured. Fifteen min. after tracer administration, rats are sacrificed by cervical dislocation. Plasma samples are collected and samples of the frontal cortex and cerebellum are removed. The level of MDL 100907 tracer is measured in each cortical and cerebellar sample. RO is calculated using the well-established ratio method which employs a region of high receptor density representative of total binding (frontal cortex) normalized by an area without or with very low levels of receptor (cerebellum). This region, referred to as the null region, represents nonspecific binding of the ligand probe. Vehicle ratio of the tracer levels in cortex relative to cerebellum represents 0% occupancy. A ratio of 1 represents 100% occupancy and is achieved when all specific binding to the 5-HT_{2A} receptor of the MDL 100907 tracer is blocked. The intermediate ratios of cortical to cerebellar tracer from the test compound pretreated group are interpolated linearly between the ratio of tracer levels in the vehicle-treated animals (0% occupancy) and a ratio of 1 (100% occupancy) in order to determine the percent 5-HT_{2A} RO.

15

MDL 100907 Analysis: Cortex and cerebellar samples are weighed and placed in conical centrifuge tubes on ice. Four volumes (w/v) of acetonitrile containing 0.1% formic acid is added to each tube. The samples are then homogenized and centrifuged at 14,000 RPM (21,920 x g) for 16 min. Supernatant is diluted by adding 100 - 900 μ L sterile water in HPLC injection vials for LC/MS/MS analysis. Analysis of MDL 100907 is carried out using an Agilent model 1200 HPLC (Agilent Technologies, Palo Alto, CA) and an API 4000 mass spectrometer. The chromatographic separation is on a 2.1 X 50 mm C18 column (Agilent part number 971700-907) with a mobile phase consisting of 60% acetonitrile in water with an overall 0.1% formic acid content. Detection of MDL 100907 is accomplished by monitoring the precursor to product ion transition with a mass to charge ratio (m/z) of 374.2 to 123.0. Standards are prepared by adding known quantities of analyte to brain tissue samples from non-treated rats and processing as described above.

25

Statistical Methods: Curves for each study are fitted to a 4 parameter logistic function with the bottom fixed at 0% using JMP® version 8.0 (SAS Institute Inc, Cary NC) and

30

the absolute ED₅₀ is calculated by the software. Values are given as means, standard errors and 95% confidence intervals. The compound of Example 2 is tested essentially as described and is found to achieve high 5-HT_{2A} receptor occupancy with an ED₅₀ of 0.41 mg/kg.

5

Inhibition of DOI Induced Headshake Activity: The *in vivo* 5-HT_{2A} receptor antagonist activity of the compound of the present invention is further demonstrated by its ability to block head shaking activity induced by the 5-HT_{2A} receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI). (see for example Bartoszyk GD, van Amsterdam C, Böttcher H, Seyfried CA. EMD 281014, a new selective serotonin 5-HT_{2A} receptor antagonist. *Eur J Pharmacol.* 2003 **473**: 229-230.) Briefly, male C57BL/6J mice (20-25 g, Charles River) are housed in standard housing conditions (32 mice in a large IVC cage, 07.00 to 19.00 light phase, constant temperature (19-23°C) and humidity (50% +/-10), ad lib food and water). Mice received either vehicle (0.25% Methyl cellulose), DOI (3 mg/kg in saline) or test compound at 10mg/kg PO plus DOI (3 mg/kg in saline). Test compounds are individually evaluated in groups of four per experiment with n=4 for each compound, together with vehicle and DOI+vehicle (n=8). After a test compound pre-treatment time of 60 min. the mice receive either vehicle (saline) or 3 mg/kg DOI dosed subcutaneously, and are then placed into clear perspex observation chambers. Five min. after DOI or vehicle administration the number of visually scored head shakes exhibited by each individual mouse is counted for 15 min. The data is analyzed using an ANOVA and post-hoc Dunnet's Test. The compound of example 2 is tested essentially as described and is found to inhibit the DOI induced headshake response produced by 3mg/kg DOI by 100% at 10 mg/kg.

25

Sleep and behavioral monitoring in rats: The compound of the present invention is tested in rats for its ability to increase the amount of sleep or decrease sleep interruption or both without undesired effects such as inhibition of REM sleep, waking motor impairment, and/or rebound insomnia. Test animals are continuously monitored by electroencephalograms (EEG), electromyograms (EMG), and motion to measure cumulative nonREM sleep, cumulative total sleep, average sleep bout duration, longest sleep bout duration, rebound insomnia, REM sleep inhibition and locomotor activity intensity during

30

wakefulness. Methods for such studies are known in the art (see for example methods described in Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. *J Pharmacology & Experimental Therapeutics* 1997; **283**: 757-769; van Gelder RN, Edgar DM, Dement

5 WC. Real-time automated sleep scoring: validation of a microcomputer-based system for mice. *Sleep* 1991, **14**: 48-55; and Gross BA, Walsh CM, Turakhia AA, Booth V, Mashour GA, Poe GR. Open-source logic-based automated sleep scoring software using electrophysiological recordings in rats. *J Neurosci Methods*. 2009; **184(1)**:10-8.)

Studies are conducted as follows:

10

Animal preparation. Adult, male Wistar rats (approximately 270-300 g at time of surgery) are surgically fitted for chronic recording of EEG, EMG, and motion as follows: Rats are surgically prepared with a cranial implant consisting of four stainless steel screws for EEG recording (two frontal [3.9 mm anterior from bregma, and ± 2.0 mm

15 mediolaterally] and two occipital [6.4 mm posterior from bregma, ± 5.5 mm mediolaterally]), and with two Teflon-coated stainless steel wires for EMG recording (positioned under the nuchal trapezoid muscles). All leads are soldered to a miniature connector (Microtech, Boothwyn, PA) prior to surgery. The implant assembly is affixed to the skull by the combination of the stainless steel EEG recording screws, cyanoacrylate

20 applied between the implant connector and skull, and dental acrylic. Locomotor activity is monitored via a miniature transmitter (Minimitter PDT4000G, Philips Respironics, Bend, OR) surgically placed into the abdomen. At least 3 weeks are allowed for recovery.

25

Recording environment. Each rat is housed individually within a microisolator cage modified with an inserted polycarbonate filter-top riser to allow more vertical headroom. A flexible cable that minimally restricts movement is connected at one end to a commutator affixed to the cage top and at the other end to the animal's cranial implant. Each cage is located within separate, ventilated compartments of a stainless steel sleep-

30 wake recording chamber. Food and water are available *ad libitum* and the ambient temperature is maintained at about $23 \pm 1^\circ\text{C}$. A 24-hr light-dark cycle (LD 12:12) using fluorescent light is maintained throughout the study. Relative humidity averages

approximately 50%. Animals are undisturbed for at least 30 hrs before and after each treatment.

Study design and dosing. The vehicle (placebo, methylcellulose 15 centipoise 0.25% in water) or one of the test compound dose levels is administered orally at 1 mL/kg pseudo-randomly such that no rat receives the same treatment twice, and no rat receives more than two of the 8 treatments in any one study. Each rat is removed from its cage for about a minute to be weighed and treated. At least 6 days “washout” period precede and follow each treatment.

Data collection. Sleep and wakefulness discrimination may be automated (e.g., Van Gelder et al. 1991 (above); Edgar et al. 1997 (above); Winrow CJ, et al., *Neuropharmacology* 2010; **58(1)**:185-94.; and Gross et al., 2009 (above). EEG is amplified and filtered (X10,000, bandpass 1-30 Hz), EMG is amplified and integrated (bandpass 10-100 Hz, RMS integration), and non-specific locomotor activity (LMA) is monitored simultaneously. Arousal states are classified in 10 second epochs as non-REM sleep, REM sleep, wakefulness, or theta-dominated wakefulness. Locomotor activity (LMA) is recorded as counts per minute and is detected by commercially available telemetry receivers (ER4000, Minimitter, Bend, OR).

Statistical Analysis. All animals having at least one outcome are included in the summary results (for example, we include appropriate data from an animal treatment for which telemetry data is usable but EEG data is not). The post-treatment observation period is divided into post-dosing intervals appropriate to each Outcome, where the time of dosing is defined as the start of Hour = 0, and outcomes are summarized in the observation period by computing either the mean hourly or the cumulative value across each period (see legend of Table 2 for precise definition of each Outcome). Sleep bouts are analyzed on the log scale to stabilize the variation, all other variates are analyzed on the linear scale. Each outcome in each period is analyzed by analysis of covariance using treatment group and treatment date as factors and the corresponding pre-treatment interval, 24 hrs earlier, as the covariate. Adjusted means and the change from vehicle means and their corresponding standard errors are summarized for each treatment group. Outcomes

analyzed on the log scale are back-transformed to report geometric means and mean ratio-to-vehicle results.

The compound of Example 2 is tested essentially as described. The compound of Example 2 is found to significantly increase cumulative NREM sleep time and
5 cumulative total sleep time without significant rebound insomnia, REM sleep inhibition or inhibition of locomotor intensity (LMI) at 3 mg/kg. (See sleep profile and locomotor activity intensity in Table 2.)

Table 2. Compound of Example 2.

Dose (mg/kg PO)	<u>Efficacy variables</u>			<u>Undesired effect variables</u>		
	<u>Cumulative NREM sleep</u>			<u>Rebound Insomnia</u>		
	<i>N</i>	Adj.Mean	SE	<i>N</i>	Adj.Mean	LCL
10	7	26.9	5.5	7	3.3	-7.0
3	9	30.1	5.1	9	1.6	-7.8
1	13	31.0	4.6	13	-0.6	-9.1
0.5	11	30.6	4.7	11	-5.0	-13.9
0.25	11	19.1	4.8	11	2.2	-6.8
0.1	8	15.4	5.5	8	-0.027	-10.3
0.025	4	-2.3	7.0	4	0.40	-12.6

Dose (mg/kg PO)	<u>Cumulative Total sleep</u>			<u>REM inhibition</u>		
	<i>N</i>	Adj.Mean	SE	<i>N</i>	Adj.Mean	LCL
	10	7	26.3	6.5	7	-7.3
3	9	31.6	6.1	9	0.042	-5.5
1	13	33.2	5.4	13	1.2	-3.6
0.5	11	32.6	5.6	11	2.3	-2.9
0.25	11	23.0	5.7	11	2.8	-2.3
0.1	8	16.9	6.5	8	-0.71	-6.7
0.025	4	3.6	8.2	4	5.0	-2.6

Dose (mg/kg PO)	<u>Average Sleep Bout</u>			<u>Locomotor Activity Intensity</u>		
	<i>N</i>	Adj.Mean	SE	<i>N</i>	Adj.Mean	LCL
	10	7	1.56	0.18	6	-0.89
3	9	1.92	0.21	9	0.01	-1.69
1	13	1.60	0.16	11	-2.33	-3.96
0.5	11	1.59	0.16	10	-1.30	-2.96
0.25	11	1.34	0.14	8	-0.31	-2.11
0.1	8	1.19	0.14	7	0.41	-1.53
0.025	4	1.08	0.16	3	-1.40	-3.97

Dose (mg/kg PO)	<u>Longest Sleep Bout</u>		
	<i>N</i>	Adj.Mean	SE
	10	7	2.12
3	9	2.16	0.28
1	13	2.16	0.25
0.5	11	1.81	0.22
0.25	11	1.55	0.18
0.1	8	1.07	0.15
0.025	4	1.26	0.23

Table 2. Outcome statistics: Abbreviations: *N* = sample size; Adj.Mean = adjusted group mean value relative to vehicle controls; SE = standard error of the mean; LCL = lower 95% confidence limit, NREM = non-REM, *i.e.*, all sleep other than REM sleep. The parallel reference vehicle group sample size was *N*=27.




Definitions and units — means are adjusted differences from vehicle controls:

- Cumulative sleep: across the first 6 hr. post-treatment, in minutes (‘Total sleep’ denotes NREM sleep + REM sleep).
- Average sleep bout: average of hourly-averaged sleep bouts, across the first 6 hr. post-treatment, expressed as *n*-fold increase over vehicle controls.
- Longest sleep bout: the longest sleep bout in the first 6 hr. post-treatment, expressed as *n*-fold increase over vehicle controls.
- Rebound insomnia: cumulative minutes of NREM+REM sleep during the first 3 hr. of the lights on period, *i.e.*, 7th, 8th and 9th hours post-treatment.
- REM inhibition: cumulative minutes of REM sleep during the first 12 hr. post-treatment.
- Locomotor Activity (LMA) Intensity: expressed as LMA counts per minute of EEG-defined wakefulness, averaged across the first 6 hr. post-treatment.

Determining efficacy. The threshold efficacy for each of the four efficacy variables is calculated by plotting the increase in each variable relative to vehicle controls during the 6 hr. period after treatment against log(dose). The threshold efficacy for each variable is that dose, estimated by 4 parameter logistic nonlinear regression, which gives the defined efficacy threshold value; +30 min. of additional accumulated non-REM sleep, +25 min. of additional accumulated total sleep, 1.75x increase in average sleep bout duration, and 1.5x increase in longest sleep bout duration. Final values are expressed in terms of freebase concentration. The compound of example 2 is found to have threshold efficacious doses as shown in Table 3.

Table 3	Estimated efficacy dose (mg/kg)	95% confidence interval (mg/kg)
NREM accumulation = 30 min.	0.78	non-estimable*
total sleep accumulation = 25 min.	0.19	0.09, 0.52
longest sleep bout (1.75-fold increase)	0.33	0.18, 0.67
average sleep bout (1.5-fold increase)	0.33	0.10, 1.1**

*n.e. = not estimable, statistically, **interpolated



Determining undesired effects. Each ‘undesired effect’ outcome variable (see Table 2 legend for definitions), is plotted against log(dose). The threshold value for REM sleep inhibition is defined as a cumulative reduction of REM sleep of -10 min. The threshold value for rebound insomnia is defined as -20 min. The threshold value for reduced LMI is defined as -5 locomotor activity counts per minute of EEG-defined wakefulness. A significant undesired effect is defined to occur when the lower confidence limit goes below the threshold value at any dose at or below 10 times the average efficacious dose,

and a dose response trend is evident for doses above the threshold efficacy dose. For the compound of Example 2, REM sleep inhibition exceeds the threshold value at 10 mg/kg, but this dose is more than 10 times the most conservative efficacy dose of 0.78 mg/kg (Table 3). Negative values indicate REM inhibition, rebound insomnia and reduced LMI. In the above plots, an asterisk marks statistical significance relative to vehicle for the given dose, but does not necessarily indicate an undesired effect. It is therefore concluded that no undesired occurrences of REM inhibition, rebound insomnia, or reduction in LMI are observed within 10 times the most conservative efficacy dose.

Plasma Clearance: It is important in a compound useful for treating sleep disorders such as insomnia that it be adequately cleared from the body with a favorable rate of clearance to avoid unwanted effects such as prolonged somnolence beyond the desired sleep period, daytime sleepiness, impaired cognition after waking, etc. The present invention provides compounds with improved rates of clearance. Rate of clearance can be assayed essentially as described below.

Male Sprague Dawley rats (body weight range 250-320 g) with indwelling femoral arterial cannulae are obtained from Charles River, Wilmington, MA 01887, USA. Test compound is administered intravenously in solution (1 mL/kg) in 20% Captisol[®] in 22.5 mM phosphate buffer, pH 2, at a final drug concentration of 1.0 mg/mL (free base equivalents). Blood samples are obtained using the indwelling cannula over 24 hr. Samples of plasma are obtained by centrifugation and stored frozen (-20°C), or on dry ice, prior to analysis.

Male Beagle dogs (body weight range 10-12 kg) are obtained from Marshall Bioresources, USA. Test compound is administered intravenously in solution (1 mL/kg) in 20% Captisol[®] in 22.5 mM phosphate buffer, pH 2, at a final drug concentration of 1.0 mg/mL (free base equivalents). Blood samples are obtained from the jugular vein over 24 hr. Samples of plasma are obtained by centrifugation and stored frozen (-20°C) prior to analysis.

Frozen plasma samples are thawed to room temperature for bioanalysis of concentrations of test compound. A related internal standard compound in acetonitrile/methanol (1:1, v/v) is added to all samples of plasma (1:1, v/v). The samples are

centrifuged to remove precipitated protein prior to analysis. The supernatants are analysed by injection and rapid gradient elution on a Javelin Betasil C18 column (20 x 2.1 mm cartridge, Mobile phase A: Water/ 1 M NH₄HCO₃ , 2000:10 v/v, Mobile Phase B: MeOH/ 1 M NH₄HCO₃ , 2000:10 v/v). The eluted analytes are detected by LC-MS-MS analysis using a Sciex API 4000 triple quadrupole mass spectrometer. Concentrations of compound are determined from standards prepared and analysed under identical conditions. Clearance is calculated using non-compartmental analysis in Watson 7.4, Thermo Fisher Scientific, Inc.

$$\text{Clearance} = \frac{\text{Dose}}{\text{Area under curve for plasma concentration / time}}$$

The compound of Example 2 is run essentially as described and is found to have a favorable clearance profile:

Example	Clearance (mL/min./Kg)
	Dog
2	6.06 (+/- 0.90)

While it is possible to administer the compounds as employed in the methods of this invention directly without any formulation, the compounds are usually administered in the form of pharmaceutical compositions comprising the compound, or a pharmaceutically acceptable salt thereof, as an active ingredient and at least one pharmaceutically acceptable carrier, diluent and/or excipient. These compositions can be administered by a variety of routes including oral, sublingual, nasal, subcutaneous, intravenous, and intramuscular. Such pharmaceutical compositions and processes for preparing them are well known in the art. See, e.g., Remington: The Science and Practice of Pharmacy (University of the Sciences in Philadelphia, ed., 21st ed., Lippincott Williams & Wilkins Co., 2005).

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 0.1 to about 60 mg, more usually about 0.5 to about 30 mg, as for example between about 1 and about 10 mg of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active

material calculated to produce the desired therapeutic effect, in association with at least one suitable pharmaceutically acceptable carrier, diluent and/or excipient.


The compounds of Formula I are generally effective over a wide dosage range. For example, dosages per day normally fall within the range of about 0.002 to about 1.0
5 mg/kg, more usually from about 0.008 to 0.5 mg/kg, and as for example between 0.015 and 0.15 mg/kg of body weight. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. It will be
10 understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

15

-26-

We Claim:

1. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1 which is an HCl salt.

10 3. A pharmaceutical composition comprising a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier, diluent, or excipient.

15 4. A method of treating insomnia in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

5. The method of Claim 4 where the mammal is a human.

20 6. The method of Claim 4 where the insomnia is characterized by difficulties in sleep onset or sleep maintenance or both.

7. The method of Claim 6 where the mammal is a human.

8. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for use in therapy.
9. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for
5 use in the treatment of insomnia.
10. The compound for use according to Claim 9, or a pharmaceutically acceptable salt thereof, where the insomnia is characterized by difficulties in sleep onset or sleep maintenance or both.
10
11. The compound for the use according to either Claim 9 or 10 in a human.
12. The use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of insomnia.
15
13. The use according to Claim 12, where the insomnia is characterized by difficulties in sleep onset or sleep maintenance or both in a mammal.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2014/010577

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C07D498/04 A61K31/55 A61P25/00
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2007/022068 A1 (HYPNION INC [US]; WHITE JAMES F [US]; SHIOSAKI KAZUMI [US]; HANGAUER D) 22 February 2007 (2007-02-22) cited in the application claim 1; compound 106 -----	1-13

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 17 February 2014	Date of mailing of the international search report 27/02/2014
---	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Grassi, Damian
--	--

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/010577

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007022068	A1	22-02-2007	
		AT 448234 T	15-11-2009
		CA 2617107 A1	22-02-2007
		EP 1915379 A1	30-04-2008
		ES 2333983 T3	03-03-2010
		JP 2009504676 A	05-02-2009
		US 2007043021 A1	22-02-2007
		WO 2007022068 A1	22-02-2007
